Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D7LZ | ISIN: KYG1933S1012 | Ticker-Symbol: N/A
NASDAQ
04.06.25 | 15:30
1,820 US-Dollar
0,00 % 0,000
1-Jahres-Chart
CASI PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CASI PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur CASI PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.05.CASI Pharmaceuticals Provides Business and Clinical Update925BEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...
► Artikel lesen
16.05.CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results265BEIJING, CN / ACCESS Newswire / May 16, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...
► Artikel lesen
14.05.CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer1
12.05.CASI Pharmaceuticals to divest Chinese assets in $20 million deal2
CASI PHARMACEUTICALS Aktie jetzt für 0€ handeln
12.05.CASI Pharmaceuticals veräußert Eigenkapital in chinesischen Tochtergesellschaften3
12.05.CASI Pharmaceuticals divests equity in Chinese subsidiaries6
12.05.CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China225BEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...
► Artikel lesen
07.05.CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer4
07.05.CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement678BEIJING, CHINA / ACCESS Newswire / May 7, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...
► Artikel lesen
09.04.CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer5
03.04.CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company305BEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...
► Artikel lesen
31.03.CASI Pharmaceuticals, Inc. - 20-F, Annual and transition report of foreign private issuers3
31.03.CASI Pharmaceuticals GAAP EPS of -$2.56, revenue of $28.54M4
31.03.CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer2
31.03.CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results290BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...
► Artikel lesen
10.02.CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer2
21.01.CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer-
06.01.CASI Pharmaceuticals: CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia437BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic...
► Artikel lesen
26.12.24CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer2
16.12.24CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer7
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1